Flow Neuroscience has secured FDA approval for FL-100, the first at-home brain stimulation device for major depressive disorder.

Agreement has been reached on the reform of EU pharma legislation, but industry thinks it does not go far enough to restore the bloc’s global

Umoja Biopharma, one of the most well-capitalized developers of in vivo CAR-T therapy, is delaying its first clinical readout from its China-based first trial. The

Share price falls of 90% are mercifully rare in biopharma — but as Rezolute discovered Thursday, not entirely unknown. The wholesale failure of the Phase

Rhythm Pharmaceuticals unveiled initial data from a mid-stage study of its MC4R agonist in patients with a rare disease that causes excessive hunger. The biotech’s